Latest / The Midday Report with Mandy Wiener / Drug manufacturers call for a crackdown on illicit obesity medications
Transcript
- 0:00Speaker 1: Something that people maybe aren't talking about enough is where
- 0:03Speaker 1: people are getting their peptides from or where they're getting
- 0:07Speaker 1: their retin-2 tried or whatever it might be. Your obesity
- 0:11Speaker 1: drug pharmaceutical manufacturers urging law enforcement agencies to crack down
- 0:16Speaker 1: on the sale of illegal medicines, saying that they need
- 0:19Speaker 1: urgent action to protect consumers and boost investor confidence.
- 0:24Speaker 2: Dr.
- 0:24Speaker 1: Stavros Nikolaou is the chair of the Pharmaceutical Task Group
- 0:30Speaker 1: and joins us now. Dr. Nikolaou, good afternoon to you.
- 0:33Speaker 1: Thanks very much for your time.
- 0:35Speaker 2: Good afternoon, Mandy. Thanks very much for having me, and
- 0:38Speaker 2: good afternoon to all that are listening in.
- 0:40Speaker 1: What is the concern of the pharmaceutical task group regarding
- 0:45Speaker 1: the proliferation of these medications?
- 0:49Speaker 2: Mandy, firstly, I'd like to draw a distinction. What we're
- 0:53Speaker 2: referencing here is not your narcotics, which are century, if
- 1:00Speaker 2: not decade-old problems. I'm not referencing heroin or or cocaine,
- 1:04Speaker 2: or mandrax, or anything like that here. I'm referencing something
- 1:08Speaker 2: that is equally disturbing and also equally dangerous, and that
- 1:15Speaker 2: is unregistered medicines or medicines that are bought in as
- 1:21Speaker 2: counterfeit or fake medicines and appear to be registered or
- 1:25Speaker 2: appear to be legitimate. So there's a further distinction I'm
- 1:28Speaker 2: drawing there. There's instances where There are registered medicines in
- 1:33Speaker 2: South Africa, and we are quite focused on the weight
- 1:37Speaker 2: loss drugs and the peptides for this conversation. We are
- 1:42Speaker 2: finding that registered medicines are being bought in illicitly, meaning
- 1:48Speaker 2: they're from dubious sources, unknown sources, or worst of all,
- 1:53Speaker 2: from sources that are either non-compliant to GMP standards. or
- 2:02Speaker 2: have no quality standard approvals. So it's a combination of things.
- 2:07Speaker 2: It's a growing problem. It seems to have exacerbated with
- 2:13Speaker 2: these GLP-1 weight loss products, which of course are understandably
- 2:18Speaker 2: in high demand. And the risks to patients and the
- 2:22Speaker 2: public is immense. You referenced Reta-Trutard earlier. I do want
- 2:27Speaker 2: to focus on Reta-Trutard for a moment. Now, retrotrutide is
- 2:32Speaker 2: a medicine that is showing a lot of potential, but
- 2:36Speaker 2: it is still in experimental stage. In other words, it's
- 2:40Speaker 2: still undergoing clinical trials to determine quality, safety, efficacy of
- 2:46Speaker 2: the product. And it's absolutely astonishing. It's almost egregious, I'd suggest,
- 2:53Speaker 2: that Before a metin is proven or registered anywhere in
- 2:57Speaker 2: the world, we are already seeing copies of that in
- 3:00Speaker 2: our own country. And yesterday at this roundtable we hosted,
- 3:04Speaker 2: there was a report of two further deaths on the
- 3:09Speaker 2: counterfeits of True Tide. And these are alarming statistics. And
- 3:15Speaker 2: if left unarrested, the problem is going to grow into
- 3:19Speaker 2: a much bigger one. And the bigger one is when
- 3:22Speaker 2: you start... losing the integrity of your pharmaceutical regulatory and
- 3:26Speaker 2: value chain, then you are in trouble as a country.
- 3:30Speaker 1: It does seem like there's been quite a proliferation. I mean,
- 3:32Speaker 1: you can get it at, you know, a few different
- 3:34Speaker 1: doctors are selling it, gyms seem to be selling it.
- 3:38Speaker 1: So how do you crack down on that? Or is
- 3:41Speaker 1: the problem the converse, Stavros, that it's just taking too
- 3:44Speaker 1: long for it to try to get the requisite authorization
- 3:50Speaker 1: in South Africa?
- 3:53Speaker 2: So let me start off with Reta True Tide again.
- 3:56Speaker 2: So Reta True Tide is still in clinical trials. So
- 4:00Speaker 2: it hasn't been registered in any country in the world.
- 4:04Speaker 2: Clinical trials have particular protocols to ensure safety for the public.
- 4:10Speaker 2: And it's not something that you can rush. You start
- 4:13Speaker 2: rushing and you're not going to get the desired quality, safety,
- 4:17Speaker 2: efficacy outcomes that you seek in the first instance. Um,
- 4:21Speaker 2: so it's, I've been in this industry for 40 years
- 4:24Speaker 2: and it's, um, for me, it's, uh, it's unprecedented where
- 4:30Speaker 2: you're getting medicines that are not registered or still in
- 4:33Speaker 2: clinical trial phases, um, entering the market. And, and that
- 4:38Speaker 2: really holds significant harm potential, as I said earlier. Now,
- 4:42Speaker 2: let me cover another aspect that you raised and, um,
- 4:48Speaker 2: There are two primary channels of illicit trade in these
- 4:53Speaker 2: type of medicines. The first is where products are entering
- 4:58Speaker 2: the country illegally. They're unregistered products. They're untested in many instances.
- 5:03Speaker 2: And they enter through our ports, usually disguised as some
- 5:11Speaker 2: or other product like cat food. We've heard about cat
- 5:15Speaker 2: food or a vitamin. So it comes in under that guise,
- 5:19Speaker 2: but is in fact a peptide or one of these
- 5:23Speaker 2: fake GLP-1 products. So that's the first source. The second
- 5:28Speaker 2: source is what we've encountered in the form of compounding. Now,
- 5:33Speaker 2: the first channel, illicit channel, usually involves non-healthcare professionals. And
- 5:42Speaker 2: these products land up with hairdressers, gym instructors, beauty salons,
- 5:48Speaker 2: et cetera. So that's non-healthcare channels. Then you've got a
- 5:55Speaker 2: phenomenon called compounding, which is permissible in law on a
- 6:01Speaker 2: patient and case-by-case basis. So compounding means that a compounding
- 6:07Speaker 2: pharmacy can compound its own product on a selective basis
- 6:13Speaker 2: on prescription basis for an individual patient. And it's usually
- 6:16Speaker 2: confined to dermatology where dermatologists ask for three or four
- 6:21Speaker 2: creams that don't exist in one proprietary brand to be
- 6:24Speaker 2: combined and usually the pharmacy will compound that. But there's
- 6:29Speaker 2: been an abuse of compounding now in that some of
- 6:35Speaker 2: these compounding pharmacies that are acting unlawfully and the courts
- 6:38Speaker 2: have proven that it is unlawful in recent times are
- 6:42Speaker 2: producing these products on mass at scale and putting patients
- 6:47Speaker 2: in jeopardy. And this is a more difficult thing to
- 6:51Speaker 2: deal with because an unsuspecting public thinks they are receiving
- 6:56Speaker 2: this from a registered healthcare professional. So I guess in conclusion,
- 7:00Speaker 2: two things need to happen here. And two things came
- 7:02Speaker 2: up very strongly yesterday. There are certain slam dunk cases
- 7:08Speaker 2: like selling an unregistered medicine is illegal, whether it's a
- 7:11Speaker 2: doctor pharmacy or a member of a public. that is
- 7:14Speaker 2: selling that it's illegal. That's a slam dunk case. Why
- 7:18Speaker 2: are the enforcement agencies taking so long to raid these facilities,
- 7:24Speaker 2: make arrests and prosecute accordingly? So that's the first thing
- 7:27Speaker 2: that's got to be accelerated. And then the second thing
- 7:30Speaker 2: is very much about educating the public. So are they
- 7:34Speaker 2: aware of this issue? And secondly, to encourage the public
- 7:39Speaker 2: to question where they're getting their medicines from. And if
- 7:42Speaker 2: they are getting medicines dubious medicines or medicines from dubious sources,
- 7:47Speaker 2: then there is a website, on the SEPRA website, there
- 7:52Speaker 2: is a facility for patients and or consumers to report
- 7:56Speaker 2: these things. Dr.
- 7:57Speaker 1: Stavros Nikolaou, thank you so much for speaking to us today.
- 8:00Speaker 1: The chairperson of the Pharmaceutical Task Group.